70 related articles for article (PubMed ID: 2510928)
1. Modulation of ovarian carcinoma tumor marker CA-125 by gamma-interferon.
Marth C; Fuith LC; Böck G; Daxenbichler G; Dapunt O
Cancer Res; 1989 Dec; 49(23):6538-42. PubMed ID: 2510928
[TBL] [Abstract][Full Text] [Related]
2. Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promoters.
Leon JA; Mesa-Tejada R; Gutierrez MC; Estabrook A; Greiner JW; Schlom J; Fisher PB
Anticancer Res; 1989; 9(6):1639-47. PubMed ID: 2516715
[TBL] [Abstract][Full Text] [Related]
3. Effects of biological response modifiers on ovarian carcinoma cell lines.
Marth C; Helmberg M; Mayer I; Fuith LC; Daxenbichler G; Dapunt O
Anticancer Res; 1989; 9(2):461-7. PubMed ID: 2502063
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells.
Allavena P; Peccatori F; Maggioni D; Erroi A; Sironi M; Colombo N; Lissoni A; Galazka A; Meiers W; Mangioni C
Cancer Res; 1990 Nov; 50(22):7318-23. PubMed ID: 2121337
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of interferon induction of class I major histocompatibility complex antigen expression by human tumor necrosis factor in small cell lung cancer cell lines.
Marley GM; Doyle LA; Ordóñez JV; Sisk A; Hussain A; Yen RW
Cancer Res; 1989 Nov; 49(22):6232-6. PubMed ID: 2553249
[TBL] [Abstract][Full Text] [Related]
7. Modulation of ovarian carcinoma OV632 antigen by interferons.
Marth C; Müller-Holzner E; Gaugg I; Daxenbichler G; Dapunt O
Oncology; 1992; 49(1):53-7. PubMed ID: 1542495
[TBL] [Abstract][Full Text] [Related]
8. Hormonal regulation of CA125 tumor marker expression in human ovarian carcinoma cells: inhibition by glucocorticoids.
Karlan BY; Amin W; Casper SE; Littlefield BA
Cancer Res; 1988 Jun; 48(12):3502-6. PubMed ID: 3285997
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of IL-6 and IFN-gamma on carcinoembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells: role for endogenous IFN-beta.
Dansky-Ullmann C; Salgaller M; Adams S; Schlom J; Greiner JW
Cytokine; 1995 Feb; 7(2):118-29. PubMed ID: 7780031
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells.
Marth C; Zeimet AG; Widschwendter M; Ludescher C; Kaern J; Tropé C; Gastl G; Daxenbichler G; Dapunt O
Cancer Res; 1997 Sep; 57(17):3818-22. PubMed ID: 9288793
[TBL] [Abstract][Full Text] [Related]
11. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma.
Munker R; Andreeff M
Cytokines Mol Ther; 1996 Sep; 2(3):147-59. PubMed ID: 9384699
[TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma.
Guerry D; Alexander MA; Elder DE; Herlyn MF
J Immunol; 1987 Jul; 139(1):305-12. PubMed ID: 3108402
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of human interferon alpha and interferon gamma on xenografted human thyroid tissue in severe combined immunodeficient mice and nude mice.
Kawai K; Enomoto T; Fornasier V; Resetkova E; Volpé R
Proc Assoc Am Physicians; 1997 Mar; 109(2):126-35. PubMed ID: 9069581
[TBL] [Abstract][Full Text] [Related]
14. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125.
Zeimet AG; Marth C; Offner FA; Obrist P; Uhl-Steidl M; Feichtinger H; Stadlmann S; Daxenbichler G; Dapunt O
Gynecol Oncol; 1996 Sep; 62(3):384-9. PubMed ID: 8812537
[TBL] [Abstract][Full Text] [Related]
15. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
[TBL] [Abstract][Full Text] [Related]
16. Effects of human recombinant alpha 2 arg-interferon and gamma-interferon on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression.
Gastl G; Marth C; Leiter E; Gattringer C; Mayer I; Daxenbichler G; Flener R; Huber C
Cancer Res; 1985 Jul; 45(7):2957-61. PubMed ID: 3924395
[TBL] [Abstract][Full Text] [Related]
17. Induction of expression of interferon-stimulated gene factor-3 (ISGF-3) proteins by interferons.
Kumar R; Korutla L
Exp Cell Res; 1995 Jan; 216(1):143-8. PubMed ID: 7529187
[TBL] [Abstract][Full Text] [Related]
18. Interferon-gamma-induced ICAM-1 and CD40 expression, complete lack of HLA-DR and CD80 (B7.1), and inconsistent HLA-ABC expression in basal cell carcinoma: a possible role for interleukin-10?
Kooy AJ; Prens EP; Van Heukelum A; Vuzevski VD; Van Joost T; Tank B
J Pathol; 1999 Feb; 187(3):351-7. PubMed ID: 10398091
[TBL] [Abstract][Full Text] [Related]
19. Differential modulation by recombinant immune interferon of the expression and shedding of HLA antigens and melanoma associated antigens by a melanoma cell line resistant to the antiproliferative activity of immune interferon.
Ziai MR; Imberti L; Tongson A; Ferrone S
Cancer Res; 1985 Nov; 45(11 Pt 2):5877-82. PubMed ID: 3931909
[TBL] [Abstract][Full Text] [Related]
20. HLA-DR synthesis induction and expression in HLA-DR-negative carcinoma cell lines of diverse origins by interferon-gamma but not by interferon-beta.
Shaw AR; Chan JK; Reid S; Seehafer J
J Natl Cancer Inst; 1985 Jun; 74(6):1261-8. PubMed ID: 3923246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
